CD33 / SIGLEC3 (Myeloid Cell Surface Antigen) Antibody - With BSA and Azide
Purified Mouse Monoclonal Antibody
|Application ||IHC, IF, FC, IP, E|
|Other Names||Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3|
|Target/Specificity||Recombinant human CD33 protein|
|Application Note||ELISA : For coating, order Ab without BSA|
Flow Cytometry : 0.5-1ug/million cells
Immunofluorescence : 0.5-1.0 µg/ml
Functional Studies : Order Ab without BSA & Azide
Immunoprecipitation : 0.5-1 µg/500ug protein lysate
Immunohistology (Frozen) (0.5-1.0 µg/ml for 30 minutes at RT).
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD33 / SIGLEC3 (Myeloid Cell Surface Antigen) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Monocytic/myeloid lineage cells.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a 67kDa glycoprotein, which is identified as CD33. It is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. CD33 is expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells. It is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.
1. Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Berndt MC: Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33). Dis Markers. 1987;5(4):215-25.
2. Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H: Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol. 1988;69(2):163-71.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.